6 results on '"Fluorodeoxyglucose PET"'
Search Results
2. Alzheimer Disease: New Concepts on Its Neurobiology and the Clinical Role Imaging Will Play
- Author
-
Clifford R. Jack
- Subjects
Pathology ,medicine.medical_specialty ,Amyloid pet ,Neuroimaging ,Fluorodeoxyglucose PET ,Cerebrospinal fluid ,Neurobiology ,Alzheimer Disease ,Fluorodeoxyglucose F18 ,Risk Factors ,mental disorders ,Prevalence ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,Aged ,Aged, 80 and over ,Amyloid beta-Peptides ,medicine.diagnostic_test ,business.industry ,Incidence ,Magnetic resonance imaging ,Middle Aged ,medicine.disease ,Magnetic Resonance Imaging ,Mr imaging ,United States ,Reviews and Commentary ,Positron emission tomography ,Positron-Emission Tomography ,Radiopharmaceuticals ,Alzheimer's disease ,business ,Neuroscience ,Biomarkers - Abstract
Alzheimer disease (AD) is one of, if not the most, feared diseases associated with aging. The prevalence of AD increases exponentially with age after 60 years. Increasing life expectancy coupled with the absence of any approved disease-modifying therapies at present position AD as a dominant public health problem. Major advances have occurred in the development of disease biomarkers for AD in the past 2 decades. At present, the most well-developed AD biomarkers are the cerebrospinal fluid analytes amyloid-β 42 and tau and the brain imaging measures amyloid positron emission tomography (PET), fluorodeoxyglucose PET, and magnetic resonance imaging. CSF and imaging biomarkers are incorporated into revised diagnostic guidelines for AD, which have recently been updated for the first time since their original formulation in 1984. Results of recent studies suggest the possibility of an ordered evolution of AD biomarker abnormalities that can be used to stage the typical 20-30-year course of the disease. When compared with biomarkers in other areas of medicine, however, the absence of standardized quantitative metrics for AD imaging biomarkers constitutes a major deficiency. Failure to move toward a standardized system of quantitative metrics has substantially limited potential diagnostic usefulness of imaging in AD. This presents an important opportunity that, if widely embraced, could greatly expand the application of imaging to improve clinical diagnosis and the quality and efficiency of clinical trials.
- Published
- 2012
3. T1 Lung Cancers: Sensitivity of Diagnosis with Fluorodeoxyglucose PET
- Author
-
Edward F. Patz, Sarah Sarvis, Edith M. Marom, and James E. Herndon
- Subjects
Adult ,Male ,medicine.medical_specialty ,Lung Neoplasms ,Carcinoid tumors ,Sensitivity and Specificity ,Diagnosis, Differential ,Fluorodeoxyglucose PET ,Fluorodeoxyglucose F18 ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Basal cell ,Registries ,Aged ,Retrospective Studies ,Aged, 80 and over ,Fluorodeoxyglucose ,Chi-Square Distribution ,Lung ,medicine.diagnostic_test ,business.industry ,Respiratory disease ,Middle Aged ,medicine.disease ,Log-rank test ,medicine.anatomical_structure ,Positron emission tomography ,Female ,Radiology ,Radiopharmaceuticals ,Nuclear medicine ,business ,Tomography, Emission-Computed ,medicine.drug - Abstract
To determine the sensitivity of fluorodeoxyglucose (FDG) positron emission tomography (PET) in patients with T1 (or =3 cm) lung cancers.One hundred eighty-five patients with 192 histopathologically proved T1 lung cancers underwent FDG PET imaging at the time of diagnosis. PET results were correlated with tumor size, histopathologic findings, and patient outcome by using the two-sample t test, exact chi(2) test, and log rank test, respectively.Of the 192 lesions, 183 (95%) that ranged in size from 0.5 to 3.0 cm in diameter (mean, 2.0 cm) were positive at PET (ie, demonstrated increased FDG uptake). Of the 192 lesions, nine (5%) that ranged in size from 0.3 to 2.5 cm in diameter (mean, 1.3 cm) were negative at PET (ie, demonstrated low FDG uptake). Patients with small tumors, as well as those with carcinoid tumors and bronchioloalveolar cell carcinoma, were more likely to have a negative PET scan (P =.004, P =.003, respectively). In addition, patients with a negative PET scan who subsequently proved to have cancer had significantly longer survival than did patients with a positive scan and cancer (P =.043).Most T1 lung cancers show increased FDG uptake on PET scans.
- Published
- 2002
4. N stage disease in patients with non-small cell lung cancer: efficacy of quantitative and qualitative assessment with STIR turbo spin-echo imaging, diffusion-weighted MR imaging, and fluorodeoxyglucose PET/CT
- Author
-
Hisanobu Koyama, Yoshimasa Maniwa, Yumiko Onishi, Wataru Nishio, Nobukazu Aoyama, Sumiaki Matsumoto, Mizuho Nishio, Daisuke Takenaka, Yoshihiro Nishimura, Kazuro Sugimura, Tomoo Itoh, Yoshiharu Ohno, and Takeshi Yoshikawa
- Subjects
Male ,medicine.medical_specialty ,Lung Neoplasms ,Inversion Time ,Multimodal Imaging ,Sensitivity and Specificity ,Fluorodeoxyglucose PET ,Fluorodeoxyglucose F18 ,Carcinoma, Non-Small-Cell Lung ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,In patient ,Prospective Studies ,Diffusion-Weighted MR Imaging ,Lung cancer ,Aged ,Neoplasm Staging ,business.industry ,Fast spin echo ,medicine.disease ,Mr imaging ,Magnetic Resonance Imaging ,Diffusion Magnetic Resonance Imaging ,Positron-Emission Tomography ,Female ,Non small cell ,Radiology ,Radiopharmaceuticals ,business ,Nuclear medicine ,Tomography, X-Ray Computed - Abstract
To prospectively compare the diagnostic capability of short inversion time inversion-recovery (STIR) turbo spin-echo (SE) imaging, diffusion-weighted (DW) magnetic resonance (MR) imaging, and fluorodeoxyglucose (FDG) combined positron emission tomography (PET) and computed tomography (CT) in N stage assessment in patients with non-small cell lung cancer (NSCLC).This prospective study was approved by the institutional review board, and written informed consent was obtained from all patients. A total of 250 consecutive patients with NSCLC (136 men; mean age, 73 years; 114 women; mean age, 72 years) prospectively underwent pretherapeutic STIR turbo SE imaging, DW MR imaging, and FDG PET/CT, as well as surgical and pathologic examinations (N0 disease, n = 157; N1 disease, n = 72; N2 disease, n = 16; N3 disease, n = 5). Lymph node-to-saline ratio (LSR), lymph node-to-muscle ratio (LMR), apparent diffusion coefficient (ADC), maximal standardized uptake value (SUV(max)), and visual scoring were assessed for 135 metastatic lymph nodes and 135 randomly selected nonmetastatic lymph nodes. Receiver operating characteristic curve analysis was used to determine feasible threshold values. Diagnostic capabilities for N stage assessment were compared with the McNemar test on a per-patient basis.When feasible, threshold values were used for quantitative assessment; sensitivity and accuracy of LSR and LMR (sensitivity, 82.8%; accuracy, 86.8%) proved to be significantly higher than those of ADC (sensitivity: 74.2%, P = .01; accuracy: 84.4%, P = .04) and SUV(max) (sensitivity: 74.2%, P = .01). For qualitative assessment, sensitivity of STIR turbo SE imaging (77.4%) was significantly higher than that of DW MR imaging (71.0%, P = .03) and FDG PET/CT (69.9%, P = .02).Quantitative and qualitative assessments of N stage disease in patients with NSCLC obtained with STIR turbo SE MR imaging are more sensitive and/or more accurate than those obtained with DW MR imaging and FDG PET/CT.http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.11110281/-/DC1.
- Published
- 2011
5. Noninvasive quantitative fluorodeoxyglucose PET studies with an estimated input function derived from a population-based arterial blood curve
- Author
-
Vijay Dhawan, David Eidelberg, Phoebe G. Spetsieris, Robert Dahl, Thomas Chaly, S. Takikawa, William Robeson, and Donald Margouleff
- Subjects
Adult ,Male ,Statistics as Topic ,Population ,Population based ,Deoxyglucose ,Fluorodeoxyglucose PET ,Fluorodeoxyglucose F18 ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,Arterial input function ,education ,Aged ,Fluorodeoxyglucose ,education.field_of_study ,medicine.diagnostic_test ,business.industry ,Brain ,Input function ,Arteries ,Middle Aged ,Positron emission tomography ,Arterial blood ,Female ,Nuclear medicine ,business ,Tomography, Emission-Computed ,medicine.drug - Abstract
The authors have developed a technique to estimate input functions from a population-based arterial blood curve in positron emission tomography (PET) studies with fluorine-18 fluorodeoxyglucose (FDG). A standardized pump injection was used in 34 subjects. A population-based blood curve was generated based on the first 10 subjects. In the remaining 24 subjects, an estimated input function (EIFa) was obtained by scaling the population-based curve with two arterial blood samples, one obtained at 10 minutes and the other at 45. Time integrals for EIFa and the real arterial input function (RIF) were in excellent agreement (r = .998, P.0001). Cerebral metabolic rates for glucose calculated with EIFa and RIF and the autoradiographic method also correlated excellently (r = .992, P.0001). Analogous correlations were achieved with arterialized venous samples as scaling factors. These results suggest that individually scaled, population-derived input functions may serve as an adequate alternative to continuous arterial blood sampling in quantitative FDG-PET imaging.
- Published
- 1993
6. Metabolism of human gliomas: assessment with H-1 MR spectroscopy and F-18 fluorodeoxyglucose PET
- Author
-
P. C. M. Van Zijl, Jeffry R. Alger, J L Black, S W Inscoe, B X DeSouza, Alberto Bizzi, Joseph A. Frank, Michael J. Fulham, M. O. Duhaney, and Chrit T. W. Moonen
- Subjects
Adult ,Male ,In vivo magnetic resonance spectroscopy ,Fluorine Radioisotopes ,Magnetic Resonance Spectroscopy ,Deoxyglucose ,Creatine ,Fluorodeoxyglucose PET ,chemistry.chemical_compound ,Nuclear magnetic resonance ,Fluorodeoxyglucose F18 ,medicine ,Humans ,Choline ,Radiology, Nuclear Medicine and imaging ,Fluorodeoxyglucose ,medicine.diagnostic_test ,Brain Neoplasms ,business.industry ,Brain ,Magnetic resonance imaging ,Glioma ,Metabolism ,Magnetic Resonance Imaging ,chemistry ,Positron emission tomography ,Female ,Nuclear medicine ,business ,Tomography, Emission-Computed ,medicine.drug - Abstract
Localized hydrogen-1 magnetic resonance (MR) spectroscopy and fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) were employed to obtain metabolic information from intracranial gliomas. Advantages and difficulties associated with comparison of results from the two modalities were realized. Forty patients were studied with H-1 MR spectroscopy. MR signal intensities from lactate, N-acetylaspartate (NAA), choline, and creatine from a volume of interest containing the tumor and a contralateral volume were obtained and evaluated. NAA signal intensities were generally decreased in the tumor spectra, and choline signal intensities were elevated. H-1 MR spectroscopy was unsuccessful in eight patients, and FDG PET scans were not obtained in four of the patients with successful MR spectroscopic examinations. Lactate signal intensity was detected in 10 of the 28 patients who had successful H-1 MR spectroscopic and FDG PET studies. Lactate signal intensities were observed in lesions shown at FDG PET to be hypermetabolic, as well as in lesions found to be hypometabolic.
- Published
- 1990
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.